Akeso Doses First Patient in Phase II Trial of TROP2/Nectin-4 Bispecific ADC Combo for Breast Cancer
Event summary
- Akeso dosed the first patient in a Phase II study (AK146D1-202) evaluating AK146D1, its TROP2/Nectin-4 bispecific ADC, combined with ivonescimab for advanced breast cancer.
- The trial focuses on first-line treatment of HR+/HER2- and triple-negative breast cancer (TNBC).
- AK146D1 is part of Akeso's IO2.0 + ADC2.0 strategy, combining immuno-oncology and next-gen ADCs to address unmet needs in breast cancer.
- Ivonescimab, a PD-1/VEGF bispecific antibody, has shown strong Phase III results across multiple indications.
The big picture
Akeso's move underscores a broader industry shift toward multi-target combination therapies to address tumor heterogeneity and resistance. The company is positioning itself as a leader in next-gen ADCs and immuno-oncology bispecifics, competing with global players in precision oncology. Success here could validate its IO2.0 + ADC2.0 strategy across other major malignancies.
What we're watching
- Combination Efficacy
- Whether the AK146D1 + ivonescimab combo can overcome resistance challenges in PD-L1-negative breast cancer patients.
- Pipeline Momentum
- The pace at which Akeso advances additional IO2.0 + ADC2.0 combinations across other high-incidence tumor indications.
- Regulatory Pathways
- How quickly Akeso can translate Phase II data into pivotal trials, given the competitive landscape in breast cancer therapies.
Related topics